title: Efficacy and safety of tigecycline monotherapy compared with vancomycin-aztreonam in the treatment of complicated skin and skin structure infections in patients from India and Taiwan.
abstract: BACKGROUND
  To compare the monotherapy of tigecycline with vancomycin-aztreonam in hospitalized patients from India and Taiwan with complicated skin and skin structure infections (cSSSIs).
  
  
  METHODS
  Safety and efficacy data were analyzed for Indian (n = 86) and Taiwanese (n = 41) patients hospitalized with cSSSIs who participated in two international Phase 3, randomized, double-blind studies.
  
  
  RESULTS
  Patients were treated for 5-14 days. Cure rates at the test-of-cure assessment (12-92 days post-therapy) were generally similar between tigecycline and vancomycin-aztreonam in the clinically evaluable populations (India, 83.3% vs. 75.8%; Taiwan, 78.6% vs. 90%) and in the clinical modified intent-to-treat populations (India, 78.6% vs. 66.7%; Taiwan, 73.3% vs. 75.0%). Nausea and vomiting occurred more frequently with tigecycline, but overall safety and tolerability were comparable between the two treatments.
  
  
  CONCLUSIONS
  Tigecycline monotherapy is a safe and effective therapy for cSSSIs in geographically distinct populations in Asia.
authors: Chi Mei Medical Center, Department of Internal Medicine, Yung Kang Dist., Tainan City, Taiwan. chuangkenneth@hotmail.com
authors: Yin-Ching
authors: YC
authors: Chuang
authors: Chia-Ming
authors: CM
authors: Chang
authors: Sacchidanand
authors: S
authors: Aradhya
authors: Bheerappa
authors: B
authors: Nagari
authors: Vishwanath
authors: V
authors: Pai
authors: Nathalie
authors: N
authors: Dartois
authors: Sylvie
authors: S
authors: Jouve
authors: Angel
authors: A
authors: Cooper
mesh_terms: D000328:Adult; D000368:Aged; D000900:Anti-Bacterial Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001398:Aztreonam / Q000009:adverse effects / Q000627:therapeutic use*; D004311:Double-Blind Method; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007194:India; D008297:Male; D008826:Microbial Sensitivity Tests; D008875:Middle Aged; D008911:Minocycline / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D009325:Nausea / Q000209:etiology; D017192:Skin Diseases, Bacterial / Q000188:drug therapy*; D013624:Taiwan; D000078304:Tigecycline; D014640:Vancomycin / Q000009:adverse effects / Q000627:therapeutic use*; D014839:Vomiting / Q000209:etiology
chemical_list: D000900:Anti-Bacterial Agents; D014640:Vancomycin; D000078304:Tigecycline; D008911:Minocycline; D001398:Aztreonam